Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Isavuconazole for the Prevention of SARS-CoV-2-associated Invasive Aspergillosis in Critically-Ill Patients

NCT04707703 is registered in ClinicalTrials.gov with Jeffrey Jenks, MD, MPH as lead sponsor.

NCT NCT04707703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04707703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Isavuconazole for the Prevention of SARS-CoV-2-associated Invasive Aspergillosis in Critically-Ill Patients
Lead sponsor
Jeffrey Jenks, MD, MPH
Phase
Phase 3
Overall status
Terminated
Start date
March 16, 2021
Completion date
October 25, 2021
Enrollment
8 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

aspergillosis invasive, severe acute respiratory syndrome coronavirus 2